氩氦刀冷冻治疗对非小细胞肺癌患者生存质量及免疫功能的影响

Effect of percutaneous targeted argon-helium cryoablation on quality of life and immune function in patients with nonsmall cell lung cancer

目的观察经皮穿刺氩氦刀冷冻治疗非小细胞肺癌对T淋巴细胞活性的影响。方法在CT引导下,对412例无法手术并经病理证实的非小细胞肺癌患者行经皮穿刺氩氦刀靶向冷冻治疗,治疗前1d及治疗后2周分别抽取外周血标本,行T细胞亚群CD3+、CD4+、CD8+、CD4+/CD8+检测,观察患者术后临床疗效、生活质量改善、不良反应及T细胞亚群变化。结果氩氦刀治疗前后外周血T细胞亚群变化显示患者术后CD3+、CD4+、CD4+/CD8+比值明显提高(均P<0.05),总有效率(CR+PR)67.7%,疾病稳定率(CR+PR+SD)89.6%,治疗后生活质量(QOL)改善363例(88.1%)、稳定30例(7.28%)。结论经皮穿刺氩氦刀冷冻治疗非小细胞肺癌有效率高,不良反应低,可以提高患者辅助T细胞活性,从而提升患者细胞免疫功能。

【Objective】To observe the influence of treating non-small cell lung cancer with percutaneous targeted argon-helium cryoablation on T-lymphocyte activity.【Methods】412 inoperable patients confirmed by pathology with non-small cell lung cancer were treated by CT guided percutaneous targeted argon-helium cryoablation. 1 day before and 2 weeks after treatment, respectively peripheral blood samples were collected to detect the CD3＋, CD4＋,CD8＋, lymphocyte subsets and CD4＋/CD8＋ratio. Besides, postoperative clinical curative effect, improvement of life quality（QOL）, adverse reactions and changes were observed. 【Results】Postoperative the CD3＋、CD4＋、CD4＋/CD8＋ratio markedly elevated, contrasted with before treatment there were significant statistical differences（P 0.05）, effective rate（CR＋PR） was 67.7%,coefficient of stabilization（CR＋PR＋SD）89.6%. In 363 cases（88.1%）, QOL improved,and in 30 cases, QOL did not change much. 【Conclusions】Percutaneous cryoablation in treatment of non-small cell lung cancer with high efficiency, low adverse reactions, can improve patients＇ quality of life, and can improve the patients＇ T helper cell activity, to enhance cellular immune function in patients.